Oct 24, 2022 8:30am EDT SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022
Oct 20, 2022 7:00am EDT SCYNEXIS Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class Antifungal
Oct 11, 2022 8:30am EDT SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022
Sep 08, 2022 8:30am EDT SCYNEXIS Presents Positive Interim Data of Ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study During the Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting
Sep 01, 2022 8:30am EDT SCYNEXIS to Present Posters Highlighting Ibrexafungerp Data at Four Upcoming Scientific Meetings in September 2022
Aug 15, 2022 7:00am EDT SCYNEXIS Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Aug 09, 2022 8:30am EDT SCYNEXIS to Report Second Quarter 2022 Financial results and Provide a Corporate Update on August 15
Aug 04, 2022 8:30am EDT SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting
Aug 01, 2022 8:30am EDT SCYNEXIS Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME® (ibrexafungerp tablets) for Prevention of Recurrent Vaginal Yeast Infections
